Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-100 and Atezolizumab in Metastatic Colorectal Cancer
NCT06012734Phase 1Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2024
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LB-100 in colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Primary endpoint: Recommended Phase 2 Dose up to 2 years. Started Jun 2024; status: recruiting.
02
Drugs
LB-100
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06012734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012734.